** Shares of drug developer Arrowhead Pharmaceuticals ARWR.O fall 11.6% to $14.91
** Bernstein analyst William Pickering says ARWR's price action reflects "increasing investor concern on partner Sarepta's SRPT.O ability to pay Arrowhead $300 million in near-term milestones" due under their 2024 partnership
** Last year, Arrowhead signed a license and collaboration agreement with Sarepta for multiple clinical and preclinical programs
** Sarepta Therapeutics' shares down 4% at $13.49
** The concerns stem from recent deaths of patients treated with Sarepta gene therapies including Elevidys; company has also refused to comply with FDA's request on Friday to halt shipments of Elevidys
** B. Riley Securities analyst Madison El-Saadi says "SRPT-partnered neuromuscular candidates are high-value and are of investor interest"
** El-Saadi calls ARWR's partnered drug programs "a lifeline" for SRPT
** Pickering also notes that "Arrowhead stock has a history of very large swings on news perceived to impact its cash position and liquidity"
** Including session's moves, ARWR down 21% YTD and SRPT down 90%
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.